Merck & Co., Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Merck & Co., Inc. (MRK) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $41.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-24
- Merck & Co., Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $41.00M, a 71.53% decline from fiscal 2024.
- Merck & Co., Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $144.00M, a 51.58% increase from fiscal 2023.
- Merck & Co., Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $95.00M, a 57.78% decline from fiscal 2022.
- Merck & Co., Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $225.00M, a 112.26% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month as first filed |
|---|---|---|
| 2025-12-31 | $41.00M 10-K · filed 2026-02-24 | |
| 2024-12-31 | $144.00M 10-K · filed 2026-02-24 | |
| 2023-12-31 | $95.00M 10-K · filed 2026-02-24 | |
| 2022-12-31 | $225.00M 10-K · filed 2025-02-25 | |
| 2021-12-31 | $106.00M 10-K · filed 2024-02-26 | |
| 2020-12-31 | $51.00M 10-K · filed 2023-02-24 | |
| 2019-12-31 | $295.00M 10-K · filed 2022-02-25 | |
| 2018-12-31 | $348.00M 10-K · filed 2021-02-25 | |
| 2017-12-31 | $236.00M 10-K · filed 2020-02-26 | |
| 2016-12-31 | $444.00M 10-K · filed 2019-02-27 | |
| 2015-12-31 | $332.00M 10-K · filed 2018-02-27 | |
| 2014-12-31 | $626.00M 10-K · filed 2017-02-28 | |
| 2013-12-31 | $374.00M 10-K · filed 2016-02-26 | |
| 2012-12-31 | $528.00M 10-K · filed 2015-02-27 | |
| 2011-12-31 | $125.00M 10-K · filed 2014-02-27 | |
| 2010-12-31 | $177.00M 10-K · filed 2013-02-28 | $117.00M 10-K · filed 2011-02-28 |
| 2009-12-31 | $119.00M 10-K · filed 2012-02-28 | |
| 2008-12-31 | $40.00M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |